Ligand Pharmaceuticals (LGND) Common Equity (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Common Equity data on file, last reported at $997.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 25.36% year-over-year to $997.3 million; the trailing twelve-month figure through Mar 2026 stood at $997.3 million (up 25.36% YoY), and the FY2025 full-year result was $1.0 billion, up 22.49% from the prior year.
• Common Equity eased to $997.3 million in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $597.5 million in Q4 2022.
• A 5-year average of $795.9 million and a median of $802.4 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity fell 27.24% in 2022 and increased 25.94% in 2024, its largest moves.
• Tracing LGND's Common Equity over 5 years: stood at $597.5 million in 2022, then advanced by 17.31% to $700.9 million in 2023, then grew by 18.48% to $830.4 million in 2024, then increased by 22.49% to $1.0 billion in 2025, then retreated by 1.96% to $997.3 million in 2026.
• Business Quant data shows LGND's Common Equity at $997.3 million in Q1 2026, $1.0 billion in Q4 2025, and $950.2 million in Q3 2025.